OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wingo on Surgical Approaches Across Gynecologic Malignancies

April 12th 2017

Shana Wingo, MD, gynecologic oncology, Arizona Oncology, discusses the various surgical approaches being explored and conducted across patients with gynecologic malignancies.

Dr. Gordon on Toxicities With Immunotherapy in Osteosarcoma

April 12th 2017

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.

Dr. Yu on Trials of Moderate Hypofractionation in Prostate Cancer

April 12th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

Dr. Quinn on Combinations of Targeted Therapy in RCC

April 11th 2017

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on combinations of targeted therapies for patients with renal cell carcinoma (RCC).

Dr. Slovin on Immunotherapy Agents for Prostate Cancer

April 11th 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses potential immunotherapy agents for patients with prostate cancer.

Dr. Dreicer on the Current Role of Abiraterone and Enzalutamide in Prostate Cancer

April 11th 2017

Robert Dreicer, MD, professor, University of Virginia Health System, discusses the current role of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) for patients with prostate cancer.

Dr. Salles on New Agents Being Investigated in Follicular Lymphoma

April 11th 2017

Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.

Dr. Gomella Discusses Immunotherapy in Bladder Cancer

April 11th 2017

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Exploring Residual Concentrations of Agents in Head and Neck Cancer

April 10th 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Dr. Sankhala on the Significance of TRC105/Pazopanib in Angiosarcoma

April 10th 2017

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses the significance of the combination of the endoglin antibody TRC105 plus pazopanib (Votrient) in patients with angiosarcoma.

Dr. Costin on Frontline Immunotherapy for Patients With NSCLC

April 8th 2017

Daniel Costin, MD, hematology and oncology, White Plains Hospital, discusses the potential with immunotherapy agents in the frontline setting as treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Pollack on the Future Treatment Landscape for Sarcoma

April 8th 2017

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.

Dr. Heymach Discusses the CheckMate-026 Study in Lung Cancer

April 7th 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.

Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer

April 7th 2017

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Targeting Galectin-1 With Radiation and Immune Checkpoints in Head and Neck Cancer

April 7th 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in head and neck cancer.

Dr. Papa on CAR T-Cell Therapy for Head and Neck Cancer

April 6th 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Study of P97 Inhibitors in Mantle Cell Lymphoma

April 6th 2017

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

Dr. Shah on Indications of Early-Onset CRC

April 6th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses indications of early-onset colorectal cancer (CRC).

Dr. Ciccolini on Residual Concentrations of Cetuximab in Head and Neck Cancer

April 6th 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses residual concentrations of cetuximab (Erbitux) in patients with head and neck cancer.

Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

April 5th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.